Clinical Cancer Research Publishes OncoMed Pharmaceuticals, Inc. Data Demonstrating Anti-Cancer Activity for Anti-DLL4 (Demcizumab) in Pancreatic Cancer
9/6/2012 10:09:49 AM
REDWOOD CITY, Calif.--(BUSINESS WIRE)--OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel therapeutics that target cancer, today announced the online publication in Clinical Cancer Research of preclinical data demonstrating the potent anti-cancer activity of anti-DLL4 (demcizumab) in patient-derived pancreatic tumor models. Demcizumab, the company’s first Notch pathway product candidate, is currently in Phase 1b clinical testing. The paper entitled “Anti-DLL4 Has Broad Spectrum Activity in Pancreatic Cancer Dependent on Targeting DLL4-Notch Signaling in Both Tumor and Vasculature Cells” was published online September 5, 2012.